These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 21967155)

  • 1. Granulocyte-colony stimulating factor use and medical costs after initial adjuvant chemotherapy in older patients with early-stage breast cancer.
    Griffiths RI; Barron RL; Gleeson ML; Danese MD; O'Hagan A; Chia VM; Legg JC; Lyman GH
    Pharmacoeconomics; 2012 Feb; 30(2):103-18. PubMed ID: 21967155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF).
    Naeim A; Henk HJ; Becker L; Chia V; Badre S; Li X; Deeter R
    BMC Cancer; 2013 Jan; 13():11. PubMed ID: 23298389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is febrile neutropenia prophylaxis with granulocyte-colony stimulating factors economically justified for adjuvant TC chemotherapy in breast cancer?
    Skedgel C; Rayson D; Younis T
    Support Care Cancer; 2016 Jan; 24(1):387-394. PubMed ID: 26081595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis.
    Wolowacz SE; Cameron DA; Tate HC; Bagust A
    J Clin Oncol; 2008 Feb; 26(6):925-33. PubMed ID: 18281666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States.
    Lyman G; Lalla A; Barron R; Dubois RW
    Curr Med Res Opin; 2009 Feb; 25(2):401-11. PubMed ID: 19192985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK.
    Liu Z; Doan QV; Malin J; Leonard R
    Appl Health Econ Health Policy; 2009; 7(3):193-205. PubMed ID: 19799473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy.
    Ramsey SD; Liu Z; Boer R; Sullivan SD; Malin J; Doan QV; Dubois RW; Lyman GH
    Value Health; 2009; 12(2):217-25. PubMed ID: 18673353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uptake and economic impact of first-cycle colony-stimulating factor use during adjuvant treatment of breast cancer.
    Hershman DL; Wilde ET; Wright JD; Buono DL; Kalinsky K; Malin JL; Neugut AI
    J Clin Oncol; 2012 Mar; 30(8):806-12. PubMed ID: 22312106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan.
    Ishiguro H; Kondo M; Hoshi SL; Takada M; Nakamura S; Teramukai S; Yanagihara K; Toi M
    Clin Ther; 2010 Feb; 32(2):311-26. PubMed ID: 20206789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.
    Tan H; Tomic K; Hurley D; Daniel G; Barron R; Malin J
    Curr Med Res Opin; 2011 Jan; 27(1):79-86. PubMed ID: 21091127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myelodysplastic syndrome and acute myeloid leukemia after receipt of granulocyte colony-stimulating factors in older patients with non-Hodgkin lymphoma.
    Calip GS; Moran KM; Sweiss KI; Patel PR; Wu Z; Adimadhyam S; Lee TA; Ko NY; Quigley JG; Chiu BC
    Cancer; 2019 Apr; 125(7):1143-1154. PubMed ID: 30548485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of Neutropenia-Related Hospitalization in Patients Who Received Colony-Stimulating Factors With Chemotherapy for Breast Cancer.
    Agiro A; Ma Q; Acheson AK; Wu SJ; Patt DA; Barron JJ; Malin JL; Rosenberg A; Schilsky RL; Lyman GH
    J Clin Oncol; 2016 Nov; 34(32):3872-3879. PubMed ID: 27646945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial.
    Nabholtz JM; Cantin J; Chang J; Guevin R; Patel R; Tkaczuk K; Vodvarka P; Lindsay MA; Reese D; Riva A; Mackey J
    Clin Breast Cancer; 2002 Oct; 3(4):268-75. PubMed ID: 12425755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of primary granulocyte-colony stimulating factor prophylaxis on neutropenic toxicity and chemotherapy dose delivery in Chinese patients with breast cancer who received adjuvant docetaxel plus cyclophosphamide chemotherapy: a retrospective cohort study.
    Kwok CCH; Wong WH; Chan LL; Wong SPY; Wang F; Wong MCS; Tse SLA
    Hong Kong Med J; 2022 Dec; 28(6):438-446. PubMed ID: 36261264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of febrile neutropenia in early stage breast cancer patients receiving adjuvant FEC-D treatment.
    Assi H; Murray J; Boyle L; Rayson D
    Support Care Cancer; 2014 Dec; 22(12):3227-34. PubMed ID: 24996828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Duration of short-acting granulocyte colony-stimulating factor for primary prophylaxis and risk of neutropenia-related hospitalization in older patients with cancer.
    Li S; Liu J; Gong T; Guo H; Gawade PL; Kelsh MA; Bradbury BD; Belani R; Lyman GH
    J Geriatr Oncol; 2020 Nov; 11(8):1309-1315. PubMed ID: 32624415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time trends in utilization of G-CSF prophylaxis and risk of febrile neutropenia in a Medicare population receiving adjuvant chemotherapy for early-stage breast cancer.
    Goyal RK; Tzivelekis S; Rothman KJ; Candrilli SD; Kaye JA
    Support Care Cancer; 2018 Feb; 26(2):539-548. PubMed ID: 28921379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy.
    Chan A; Fu WH; Shih V; Coyuco JC; Tan SH; Ng R
    Support Care Cancer; 2011 Apr; 19(4):497-504. PubMed ID: 20232087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cost-effectiveness of primary prophylaxis with PEG-rhG-CSF in early-stage breast cancer patients receiving chemotherapy in China].
    Xia W; Wang SS; Hu H; Zhao FL; Xu F; Hong RX; Jiang KK; Yuan ZY; Shi YX; Zhao K; Huang JJ; Xue C; Bi XW; Lu QY; An X; Zhang JM
    Zhonghua Zhong Liu Za Zhi; 2020 Oct; 42(10):861-867. PubMed ID: 33113628
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical Outcomes and Cost-effectiveness of Primary Prophylaxis of Febrile Neutropenia During Adjuvant Docetaxel and Cyclophosphamide Chemotherapy for Breast Cancer.
    Yu JL; Chan K; Kurin M; Pasetka M; Kiss A; Sridhar SS; Warner E
    Breast J; 2015; 21(6):658-64. PubMed ID: 26387577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.